Literature DB >> 20933560

Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice.

Alessandra Rotondo1, Antonella Amato, Laura Lentini, Sara Baldassano, Flavia Mulè.   

Abstract

Glucagon-like-peptide-1 (GLP-1) is a proglucagon-derived peptide expressed in the intestinal enteroendocrine-L cells and released after meal ingestion. GLP-1 reduces postprandial glycemia not only by its hormonal effects, but also by its inhibitory effects on gastrointestinal motility. Recently, we showed that GLP-1 acts in the enteric nervous system of mouse intestine. Therefore our working hypothesis was that GLP-1 may have also a direct influence on the gastric mechanical activity since the major part of experimental studies about its involvement in the regulation of gastric motility have been conducted in in vivo conditions. The purposes of this study were (i) to examine exogenous GLP-1 effects on mouse gastric mechanical activity using isolated whole stomach; (ii) to clarify the regional activity of GLP-1 using circular muscular strips from gastric fundus or antrum; (iii) to analyze the mechanism of action underlying the observed effects; (iv) to verify regional differences of GLP-1 receptors (GLP-1R) expression by RT-PCR. In the whole stomach GLP-1 caused concentration-dependent relaxation significantly anatagonized by exendin (9-39), an antagonist of GLP-1R and abolished by tetrodotoxin (TTX) or N(ω)-nitro-l-arginine methyl ester (l-NAME), inhibitor of nitric oxide (NO) synthase. GLP-1 was without any effect in fundic strips, but it induced concentration-dependent relaxation in carbachol-precontracted antral strips. The effect was abolished by TTX or l-NAME. RT-PCR analysis revealed a higher expression of GLP-1R mRNA in antrum than in fundus. These results suggest that exogenous GLP-1 is able to reduce mouse gastric motility by acting peripherally in the antral region, through neural NO release.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20933560     DOI: 10.1016/j.peptides.2010.09.028

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  10 in total

1.  Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro.

Authors:  Sara Baldassano; Guo-Du Wang; Flavia Mulè; Jackie D Wood
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-11-10       Impact factor: 4.052

2.  Diabetes-related alterations in the enteric nervous system and its microenvironment.

Authors:  Mária Bagyánszki; Nikolett Bódi
Journal:  World J Diabetes       Date:  2012-05-15

3.  Identification of expression and function of the glucagon-like peptide-1 receptor in colonic smooth muscle.

Authors:  Alexander T May; Molly S Crowe; Bryan A Blakeney; Sunila Mahavadi; Hongxia Wang; John R Grider; Karnam S Murthy
Journal:  Peptides       Date:  2018-11-30       Impact factor: 3.750

4.  Exogenous glucagon-like peptide-1 acts in sites supplied by the cranial mesenteric artery to reduce meal size and prolong the intermeal interval in rats.

Authors:  Kasey E Williams; Martha C Washington; Tanisha Johnson-Rouse; Ruth E Johnson; Corren Freeman; Chris Reed; John Heath; Ayman I Sayegh
Journal:  Appetite       Date:  2015-09-30       Impact factor: 3.868

5.  An inter-organ neural circuit for appetite suppression.

Authors:  Tong Zhang; Matthew H Perkins; Hao Chang; Wenfei Han; Ivan E de Araujo
Journal:  Cell       Date:  2022-06-02       Impact factor: 66.850

6.  Glucagon-like peptide-2 treatment improves glucose dysmetabolism in mice fed a high-fat diet.

Authors:  Sara Baldassano; Antonella Amato; Gaetano Felice Caldara; Flavia Mulè
Journal:  Endocrine       Date:  2016-01-30       Impact factor: 3.633

Review 7.  Impact of Intestinal Peptides on the Enteric Nervous System: Novel Approaches to Control Glucose Metabolism and Food Intake.

Authors:  Anne Abot; Patrice D Cani; Claude Knauf
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-22       Impact factor: 5.555

Review 8.  Therapeutic peptides: current applications and future directions.

Authors:  Lei Wang; Nanxi Wang; Wenping Zhang; Xurui Cheng; Zhibin Yan; Gang Shao; Xi Wang; Rui Wang; Caiyun Fu
Journal:  Signal Transduct Target Ther       Date:  2022-02-14

9.  A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects.

Authors:  Jolene Kay Berg; Eric H Kim; Benjamin Li; Bo Joelsson; Nader N Youssef
Journal:  BMC Gastroenterol       Date:  2014-02-12       Impact factor: 3.067

10.  Differential hypoglycaemic, anorectic, autonomic and emetic effects of the glucagon-like peptide receptor agonist, exendin-4, in the conscious telemetered ferret.

Authors:  Zengbing Lu; Nathalie Percie Du Sert; Sze Wa Chan; Chi-Kong Yeung; Ge Lin; David T W Yew; Paul L R Andrews; John A Rudd
Journal:  J Transl Med       Date:  2014-12-10       Impact factor: 5.531

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.